Holen Sie sich die Stockscreener-App
1.675
4.42%
-0.0775
Schlusskurs vom Vortag:
$1.7525
Offen:
$1.76
24-Stunden-Volumen:
48,734
Relative Volume:
1.87
Marktkapitalisierung:
$10.29M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-14.29M
KGV:
-0.4198
EPS:
-3.99
Netto-Cashflow:
$-12.27M
1W Leistung:
+2.45%
1M Leistung:
-2.62%
6M Leistung:
-50.30%
1J Leistung:
-59.05%
1-Tages-Spanne:
$1.66
$1.7995
1-Wochen-Bereich:
$1.48
$1.91
52-Wochen-Spanne:
$1.412
$5.01
Aprea Therapeutics Inc Stock (APRE) Company Profile
Firmenname
Aprea Therapeutics Inc
Sektor
Branche
Telefon
215-948-4119
Adresse
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Vergleichen Sie APRE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
APRE
Aprea Therapeutics Inc
|
1.675 | 10.29M | 0 | -14.29M | -12.27M | -3.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-12-28 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | Eingeleitet | Berenberg | Buy |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-06-22 | Eingeleitet | H.C. Wainwright | Neutral |
| 2020-04-21 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-10-28 | Eingeleitet | JP Morgan | Neutral |
| 2019-10-28 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2019-10-28 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Aprea Therapeutics Inc Aktie (APRE) Neueste Nachrichten
Chronic Lymphocytic Leukemia Pipeline Appears Robust With 55+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
CoreWeave Stock Skyrockets 137% In A Month: Hold Or Fold? - Barchart.com
Block Inc. Has Unusual Put Option ActivityShowing Bullish XYZ Investors - Barchart.com
Ostara Inc. Launches CG P2X In Western Canada: Phosphorus, Perfected - Barchart.com
Stocks In Play: WSP Global Inc. - Barchart.com
Alzheimer’s Disease Pipeline Appears Robust With 200+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - Barchart.com
Polycystic Kidney Disease Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - Barchart.com
Dry Eye Syndrome Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight - Barchart.com
Supporting 2SLGBTQI+ Communities For A Safer, More Equitable And Inclusive Canada - Barchart.com
Artios' AACR Data Success: What It Means For Aprea Therapeutics' ATRN-119 Program - Barchart.com
REKO INTERNATIONAL GROUP INC. TO BUY BACK UP TO 276,066 OF ITS COMMON SHARES - Barchart.com
Aprea Therapeutics Confirms Directors and Accounting Firm - TipRanks
Stocks Finish Sharply Higher On A Resilient US Labor Market - Barchart.com
Compass Refresh, Inc. Launches New Headquarters in Sulphur Springs, TX – Bringing High-Quality Exterior Maintenance Across the Southern Region - Barchart.com
Aprea Therapeutics Teams Up with MD Anderson for Preclinical HNSCC Research - MSN
Aprea Therapeutics expands cancer drug patent portfolio - MSN
Stocks In Play: Aimia Inc. - Barchart.com
ADF GROUP INC. Q1-2026 CONFERENCE CALL INVITATION - Barchart.com
BNP Paribas Financial Markets Takes $43,000 Position in Aprea Therapeutics, Inc. (NASDAQ:APRE) - Defense World
Galaxy Digital Inc. Announces Public Offering Of Common Stock - Barchart.com
Vermilion Energy Inc. Advances Strategic Portfolio Repositioning with Agreement to Sell its Saskatchewan Assets and Accelerate Debt Repayment - Barchart.com
Acute Myeloid Leukemia Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight - openPR.com
Ovarian Cancer Drugs Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight - openPR.com
Q2 Earnings Estimate for APRE Issued By Wedbush - Defense World
Eton Pharmaceuticals (NASDAQ:ETON) Earns “Buy” Rating from B. Riley - Defense World
The Manufacturers Life Insurance Company Sells 752 Shares of Pediatrix Medical Group, Inc. (NYSE:MD) - Defense World
The Manufacturers Life Insurance Company Purchases 993 Shares of CTO Realty Growth, Inc. (NYSE:CTO) - Defense World
InMode Ltd. (NASDAQ:INMD) Shares Sold by The Manufacturers Life Insurance Company - Defense World
What is Wedbush’s Estimate for ORKA FY2029 Earnings? - Defense World
Wedbush Forecasts Lower Earnings for Aprea Therapeutics - Defense World
Petro-Victory Energy Corp. Announces Short Term Loan - Barchart.com
Stocks Close Higher On Optimism Over US Trade Negotiations - Barchart.com
Ontario Lottery And Gaming CorporationMidDay Lottery Winning NumbersMay 16, 2025 - Barchart.com
Becton, Dickinson And Company Stock: Analyst Estimates & Ratings - Barchart.com
CORRECTION FROM SOURCE: Adia Nutrition Inc. Successfully Uplists to OTCQB Venture Market in Record-Breaking Six Weeks and Completes SEC Rule 15c2-11 Compliance - Barchart.com
Strathcona Resources Ltd. Reports First Quarter 2025 Financial and Operating Results, Announces Quarterly Dividend and Investment in MEG Energy Corp. - Barchart.com
Aprea Therapeutics Reports Q1 2025 Progress and Financials - TipRanks
NoticeGO-TO DEVELOPMENTS HOLDINGS INC., GO-TO SPADINA ADELAIDE SQUARE INC., FURTADO HOLDINGS INC., and OSCAR FURTADO, File No. 2022-8 - Barchart.com
RBC Global Asset Management Inc. Announces RBC ETF Cash Distributions For May 2025 - Barchart.com
Strathcona Resources Ltd. Announces Sale of Montney Business for $2.84 Billion and Acquisition of Hardisty Rail Terminal - Barchart.com
BIG ROCK BREWERY INC. ANNOUNCES RESULTS OF ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS - Barchart.com
Psychemedics Named “Most Innovative Drug Testing Company Of The Year” - Barchart.com
This Under-The-Radar Cancer Biotech Reports 21% Tumor Shrinkage: Analysts See 600%+ Upside - Barchart.com
GFL Environmental Inc. Announces Results From Annual General Meeting Of Shareholders - Barchart.com
Aprea (APRE) Reports Q1 Revenue Drop Amid Clinical Progress | AP - GuruFocus
APRE Reports Decrease in Cash Reserves by End of Q1 2025 | APRE Stock News - GuruFocus
Aprea Therapeutics Reports Promising Q1 2025 Results - TipRanks
Aprea Therapeutics reports Q1 EPS (66c) vs. (67c) last year - TipRanks
Aprea Therapeutics, Inc. SEC 10-Q Report - TradingView
Aprea Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update - The Manila Times
Finanzdaten der Aprea Therapeutics Inc-Aktie (APRE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Aprea Therapeutics Inc-Aktie (APRE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Duey Marc | Director |
Oct 18 '24 |
Sale |
4.58 |
6,462 |
29,583 |
233,651 |
| Gilad Oren | President/CEO |
Oct 23 '24 |
Buy |
3.92 |
500 |
1,958 |
333,395 |
| Duey Marc | Director |
Oct 16 '24 |
Buy |
4.39 |
30,000 |
131,700 |
240,113 |
| Gilad Oren | President/CEO |
Oct 15 '24 |
Buy |
2.90 |
250 |
725 |
332,895 |
| Duey Marc | Director |
Oct 14 '24 |
Buy |
2.58 |
190 |
490 |
210,113 |
| Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr |
Oct 11 '24 |
Buy |
2.46 |
50 |
123 |
19,368 |
| Seizinger Bernd R. | Director |
Oct 11 '24 |
Buy |
2.68 |
10,000 |
26,800 |
44,730 |
| Gilad Oren | President/CEO |
Oct 14 '24 |
Buy |
2.59 |
1,000 |
2,590 |
332,645 |
| Gilad Oren | President/CEO |
Oct 10 '24 |
Buy |
2.54 |
150 |
381 |
331,645 |
| Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr |
Oct 10 '24 |
Buy |
2.61 |
450 |
1,174 |
19,318 |
1.11%
1.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):